Drug Trial Radar · NCT05273827
Effect of Neoadjuvant Anti-PD-1 Immunotherapy on Perioperative Analgesia and Postoperative Delirium
Last checked: Nov 20, 2026Latest source record: Jan 5, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
81
Actual
Start
Mar 22, 2022
Primary completion
Dec 20, 2023
Study completion Jan 2, 2024
Sponsor
- Lead sponsor
- Tianjin Medical University Cancer Institute and HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Tianjin Medical University General Hospital; Tianjin Chest Hospital
- First posted
- Mar 10, 2022
Design
- Study type
- Observational
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To observe the effect of preoperative anti-PD-1 monotherapy combined with chemotherapy on patients' perioperative pain and opioid analgesia, and evaluate its effect on the incidence and severity of patients' postoperative delirium.
Conditions
- Immunotherapy
- Analgesia
- NSCLC
- Delirium
Interventions
neoadjuvant immunotherapyDrug
Anti-PD-1 antibody was added to the conventional neoadjuvant chemotherapy.
Neoadjuvant chemotherapyDrug
Cis-platinum combined with paclitaxel or pemetrexed
Primary outcomes
What the sponsor says the trial is designed to measure.
- perioperative opioids consumptionTime frame: from beginning of surgery to day 3 after surgery
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Tianjin Chest Hospital
Tianjin, China
Tianjin Medical University General Hospital
Tianjin, China
Tianjin Medical University Cancer Institute and Hospital
Tianjin, Tianjin Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.